British HIV Association guidelines for the management of HIV-2 2021
HIV Med
.
2021 Dec:22 Suppl 4:1-29.
doi: 10.1111/hiv.13204.
Authors
Iain Reeves
1
,
Ben Cromarty
2
,
Jane Deayton
3
,
Rageshri Dhairyawan
4
,
Mike Kidd
5
,
Chris Taylor
6
,
John Thornhill
4
,
Maya Tickell-Painter
7
,
Clare van Halsema
8
Affiliations
1
Consultant in HIV Medicine, Homerton University Hospital NHS Trust, London, UK.
2
UK Community Advisory Board representative.
3
Clinical Senior Lecturer in HIV, Barts and the London, Queen Mary University of London, London, UK.
4
Consultant in Sexual Health and HIV Medicine, Barts Health NHS Trust, London, UK.
5
Consultant Virologist, National Infection Service, Public Health England, UK.
6
Consultant Physician Sexual Health and HIV, Kings College Hospital, London, UK.
7
Specialist Registrar in Infectious Diseases and Microbiology, Manchester University NHS Foundation Trust, Manchester, UK.
8
Consultant in Infectious Diseases, North Manchester General Hospital, Manchester, UK.
PMID:
34927347
DOI:
10.1111/hiv.13204
No abstract available
Keywords:
CD4; HIV-2; antiretroviral.
MeSH terms
Anti-HIV Agents* / therapeutic use
Antiretroviral Therapy, Highly Active
CD4 Lymphocyte Count
HIV Infections* / drug therapy
HIV-2
Humans
Substances
Anti-HIV Agents